- Home
- MCRB vs GRX Comparison
MCRB vs GRX Comparison
Compare MCRB & GRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- GRX
- Stock Information
- Founded
- MCRB 2010
- GRX 2007
- Country
- MCRB United States
- GRX United States
- Employees
- MCRB N/A
- GRX N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- GRX Finance/Investors Services
- Sector
- MCRB Health Care
- GRX Finance
- Exchange
- MCRB Nasdaq
- GRX Nasdaq
- Market Cap
- MCRB 142.0M
- GRX 160.8M
- IPO Year
- MCRB 2015
- GRX N/A
- Fundamental
- Price
- MCRB $0.85
- GRX $10.92
- Analyst Decision
- MCRB Buy
- GRX
- Analyst Count
- MCRB 4
- GRX 0
- Target Price
- MCRB $4.17
- GRX N/A
- AVG Volume (30 Days)
- MCRB 5.4M
- GRX 39.7K
- Earning Date
- MCRB 10-31-2024
- GRX 01-01-0001
- Dividend Yield
- MCRB N/A
- GRX 5.98%
- EPS Growth
- MCRB N/A
- GRX N/A
- EPS
- MCRB N/A
- GRX 0.26
- Revenue
- MCRB $374,000.00
- GRX N/A
- Revenue This Year
- MCRB N/A
- GRX N/A
- Revenue Next Year
- MCRB N/A
- GRX N/A
- P/E Ratio
- MCRB N/A
- GRX $38.50
- Revenue Growth
- MCRB N/A
- GRX N/A
- 52 Week Low
- MCRB $0.54
- GRX $7.73
- 52 Week High
- MCRB $2.06
- GRX $10.40
- Technical
- Relative Strength Index (RSI)
- MCRB 42.22
- GRX 47.20
- Support Level
- MCRB $0.80
- GRX $10.73
- Resistance Level
- MCRB $1.07
- GRX $11.15
- Average True Range (ATR)
- MCRB 0.12
- GRX 0.14
- MACD
- MCRB -0.02
- GRX -0.05
- Stochastic Oscillator
- MCRB 12.26
- GRX 37.25
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.